At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 286 enrolled
Drug / intervention
KPT-330drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 in Patients With Advanced Hematological Malignancies
In Brief
A Phase 1 clinical trial evaluating KPT-330 for Hematological Malignancies. Completed, enrolled 286 participants across 12 sites in 3 countries.
Detailed Summary
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the effects of KCP-330 on the body (pharmacodynamics or PDn) and to obtain information on its effectiveness in treating cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesCanada, Denmark, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionOct 2015
TodayJul 2026
First PostedMay 30, 2012
Enrollment StartJul 23, 2012
Primary CompletionOct 13, 2015
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.1 years ago
Interventions
KPT-330drug